Publication

The genetics of asthma and the promise of genomics-guided drug target discovery

El-Husseini, Z. W., Gosens, R., Dekker, F. & Koppelman, G. H., 7-Sep-2020, In : The Lancet. Respiratory Medicine. 8, 10, p. 1045-1056 13 p.

Research output: Contribution to journalReview articleAcademicpeer-review

APA

El-Husseini, Z. W., Gosens, R., Dekker, F., & Koppelman, G. H. (2020). The genetics of asthma and the promise of genomics-guided drug target discovery. The Lancet. Respiratory Medicine, 8(10), 1045-1056. https://doi.org/10.1016/S2213-2600(20)30363-5

Author

El-Husseini, Zaid W ; Gosens, Reinoud ; Dekker, Frank ; Koppelman, Gerard H. / The genetics of asthma and the promise of genomics-guided drug target discovery. In: The Lancet. Respiratory Medicine. 2020 ; Vol. 8, No. 10. pp. 1045-1056.

Harvard

El-Husseini, ZW, Gosens, R, Dekker, F & Koppelman, GH 2020, 'The genetics of asthma and the promise of genomics-guided drug target discovery', The Lancet. Respiratory Medicine, vol. 8, no. 10, pp. 1045-1056. https://doi.org/10.1016/S2213-2600(20)30363-5

Standard

The genetics of asthma and the promise of genomics-guided drug target discovery. / El-Husseini, Zaid W; Gosens, Reinoud; Dekker, Frank; Koppelman, Gerard H.

In: The Lancet. Respiratory Medicine, Vol. 8, No. 10, 07.09.2020, p. 1045-1056.

Research output: Contribution to journalReview articleAcademicpeer-review

Vancouver

El-Husseini ZW, Gosens R, Dekker F, Koppelman GH. The genetics of asthma and the promise of genomics-guided drug target discovery. The Lancet. Respiratory Medicine. 2020 Sep 7;8(10):1045-1056. https://doi.org/10.1016/S2213-2600(20)30363-5


BibTeX

@article{a06995bf6d0a490899f46c0c78acbd07,
title = "The genetics of asthma and the promise of genomics-guided drug target discovery",
abstract = "Asthma is an inflammatory airway disease that is estimated to affect 339 million people globally. The symptoms of about 5-10% of patients with asthma are not adequately controlled with current therapy, and little success has been achieved in developing drugs that target the underlying mechanisms of asthma rather than suppressing symptoms. Over the past 3 years, well powered genetic studies of asthma have increased the number of independent asthma-associated genetic loci to 128. In this Series paper, we describe the immense progress in asthma genetics over the past 13 years and link asthma genetic variants to possible drug targets. Further studies are needed to establish the functional significance of gene variants associated with asthma in subgroups of patients and to describe the biological networks within which they function. The genomics-guided discovery of plausible drug targets for asthma could pave the way for the repurposing of existing drugs for asthma and the development of new treatments.",
author = "El-Husseini, {Zaid W} and Reinoud Gosens and Frank Dekker and Koppelman, {Gerard H}",
note = "Copyright {\textcopyright} 2020 Elsevier Ltd. All rights reserved.",
year = "2020",
month = sep,
day = "7",
doi = "10.1016/S2213-2600(20)30363-5",
language = "English",
volume = "8",
pages = "1045--1056",
journal = "The Lancet. Respiratory Medicine",
issn = "2213-2600",
publisher = "ELSEVIER SCI LTD",
number = "10",

}

RIS

TY - JOUR

T1 - The genetics of asthma and the promise of genomics-guided drug target discovery

AU - El-Husseini, Zaid W

AU - Gosens, Reinoud

AU - Dekker, Frank

AU - Koppelman, Gerard H

N1 - Copyright © 2020 Elsevier Ltd. All rights reserved.

PY - 2020/9/7

Y1 - 2020/9/7

N2 - Asthma is an inflammatory airway disease that is estimated to affect 339 million people globally. The symptoms of about 5-10% of patients with asthma are not adequately controlled with current therapy, and little success has been achieved in developing drugs that target the underlying mechanisms of asthma rather than suppressing symptoms. Over the past 3 years, well powered genetic studies of asthma have increased the number of independent asthma-associated genetic loci to 128. In this Series paper, we describe the immense progress in asthma genetics over the past 13 years and link asthma genetic variants to possible drug targets. Further studies are needed to establish the functional significance of gene variants associated with asthma in subgroups of patients and to describe the biological networks within which they function. The genomics-guided discovery of plausible drug targets for asthma could pave the way for the repurposing of existing drugs for asthma and the development of new treatments.

AB - Asthma is an inflammatory airway disease that is estimated to affect 339 million people globally. The symptoms of about 5-10% of patients with asthma are not adequately controlled with current therapy, and little success has been achieved in developing drugs that target the underlying mechanisms of asthma rather than suppressing symptoms. Over the past 3 years, well powered genetic studies of asthma have increased the number of independent asthma-associated genetic loci to 128. In this Series paper, we describe the immense progress in asthma genetics over the past 13 years and link asthma genetic variants to possible drug targets. Further studies are needed to establish the functional significance of gene variants associated with asthma in subgroups of patients and to describe the biological networks within which they function. The genomics-guided discovery of plausible drug targets for asthma could pave the way for the repurposing of existing drugs for asthma and the development of new treatments.

U2 - 10.1016/S2213-2600(20)30363-5

DO - 10.1016/S2213-2600(20)30363-5

M3 - Review article

C2 - 32910899

VL - 8

SP - 1045

EP - 1056

JO - The Lancet. Respiratory Medicine

JF - The Lancet. Respiratory Medicine

SN - 2213-2600

IS - 10

ER -

ID: 133644691